atypical endometrial hyperplasia and endometrial carcinoma endometrial carcinoma
Conditions
Interventions
Randomization to 3 group and administration of study drug (Metformin)
Metformin
Sponsors
Mitsuhashi Akira
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Histologically confirmed AEH or well-defferentiated endometrioid adenocarcinoma, presumed to be International Federation of Gynecology and Obsterics IA, and in which the EC was limited to the endometrium. Endometrial tissue sampling for diagnosis was performed by dilatation and curettage. 2. No prior treatment with a high dose of progestin, the levonorgestrel-releasing intrauterine system, or chemotherapy for an endometrial lesion (the uses of low or medium doses of a progestin for menstrual cycle regulation were permitted). 3. Over 18 years of age and under 42 years of age 4. Eastern Cooperative Oncology Group Performance Status 0 5. Fulfillment of each of the following parameters 6. No prior medical history of chemical sensitivity to any of the chemicals being used in the trial (MPA and metformin) 7. No clinical problem on electrocardiography 8. The patient and legally acceptable representative provided written informed consent
Exclusion criteria
Exclusion criteria: 1.Contraindication to the drugs used in this trial (MPA and metformin) 1.1.Susceptible to lactic acidosis 1.1.1.A history of lactic acidosis 1.1.2.Moderate to severe kidney damage or dialysis 1.1.3.Severe liver damage 1.1.4.Shock, cardiac arrest, cardiac infarction, thrombosis of the lung, or severe cardiovascular and/or lung damage 1.1.5.Ingestion of excessive amounts of alcohol 1.1.6.Gastrointestinal damage such as dehydration or diarrhea and/or vomiting that could cause dehydration 1.2.Serious ketosis, diabetic coma or pre-coma, or type I diabetes 1.3.Serious infections and/or injuries, a medical history including recent surgery, or the expectation that the patient will soon undergo surgery 1.4.Malnourishment or starvation, hyposthenia, or pituitary and/or adrenal gland disorders 1.5.Pregnancy or the expectation that the woman could be pregnant 1.6.Prior medical history of chemical sensitivity to biguanides or the compounds present in the drugs being tested 1.7.High risk of thrombosis 1.7.1.Surgery within the past week, cerebral and/or cardiac infarction, thrombophlebitis or a prior history thereof, valvular heart disease, atrial fibrillation, endocarditis, other serious cardiac conditions, or the current administration of hormone treatments 1.8.Undiagnosed breast lesions or vaginal and/or urinary bleeding 1.9.Serious liver damage 1.10.Hypocalcemia 2.Psychosis or mental symptoms that could make it difficult for patients to participate in the trial 3.Uncontrolled diabetes mellitus 4.Diabetic patients who already take biguanides, including metformin (patients who manage their diabetes via diet and exercise therapy, or those who take medicines apart from metformin are eligible). 5.Concomitant malignancies 6.Systemic administration of steroids 7.Determined to be ineligible by the physician in charge for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The three-year disease-free survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease-free survival rate The overall response rate to MPA therapy Conception rate following treatment The outcome of pregnancy Toxicity evaluation Changes in insulin resistance and body mass index (BMI) | — |
Contacts
Public ContactClinical trial coordinating office
Chiba University Hospital
Outcome results
None listed